Cationic DOTAP/DC-CHOL Liposome Adjuvants (F50101V)

$655.00

SKU: F50101V Category:
SKUStock SIZE (ml) PriceQuantity
F50101V Yes 2 ML $655.00
spinner

Description

DOTAP/DC-CHOL Cationic Liposomes

Lipid composition: DOTAP/DC-Cholesterol (50:50 mol/mol)

Mean particle size: 50-80 nm (by DSL)

Lipid concentration: 40 mM (24.7 mg/mL)

Volume: 2.0 mL

Bulk solution: D5W (dextrose in milli-Q water)

Shelf-life: 6 months guaranteed for sterility for unopened vials stored at 2-8 degree C (guaranteed starting from the date of delivery, replacement only)

 

DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)

DC-CHOL: DC-Cholesterol∙HCl, 3b-[N-(N’,N’-dimethylaminoethane)-caramoyl]chelesterol hydrochloride 

Additional information

SIZE (ml)

2 ML

Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2017 Jan 26;10(1):68. doi: 10.1186/s13104-017-2380-8.PMID: 28126014

Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.

Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.Int Immunopharmacol. 2018 Aug;61:385-393.

Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N’,N’-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.

Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y.Mol Pharm. 2011 Feb 7;8(1):153-61.

Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.

Qu W, Li N, Yu R, Zuo W, Fu T, Fei W, Hou Y, Liu Y, Yang J.Artif Cells Nanomed Biotechnol. 2018;46(sup1):852-860.

Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.

Tada R, Hidaka A, Iwase N, Takahashi S, Yamakita Y, Iwata T, Muto S, Sato E, Takayama N, Honjo E, Kiyono H, Kunisawa J, Aramaki Y.PLoS One. 2015 Oct 6;10(10):e0139785. doi: 10.1371/journal.pone.0139785. eCollection 2015.PMID: 26440657

Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.

Hadinoto K, Sundaresan A, Cheow WS.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43.

Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.

Tada R, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2018 Jul 13;11(1):472.

Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach.

Soema PC, Willems GJ, Jiskoot W, Amorij JP, Kersten GF.Eur J Pharm Biopharm. 2015 Aug;94:427-35.

Liposome-mediated DNA immunisation via the subcutaneous route.

Perrie Y, McNeil S, Vangala A.J Drug Target. 2003;11(8-10):555-63.

Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivo vaccination studies.

McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y.Curr Drug Deliv. 2010 Apr;7(2):175-87.

A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.Vaccine. 2006 May 1;24(18):3990-4006.

Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.

Gao J, Ochyl LJ, Yang E, Moon JJ.Int J Nanomedicine. 2017 Feb 14;12:1251-1264.

Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection.

Cheng JY, Huang HN, Tseng WC, Li TL, Chan YL, Cheng KC, Wu CJ.J Control Release. 2009 May 5;135(3):242-9.

Reviews

There are no reviews yet.


Be the first to review “Cationic DOTAP/DC-CHOL Liposome Adjuvants (F50101V)”